MindWalk Holdings Corp. (NASDAQ:HYFT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of MindWalk Holdings Corp. (NASDAQ:HYFT) have received an average recommendation of “Moderate Buy” from the five research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $5.00.

HYFT has been the subject of a number of recent research reports. Weiss Ratings restated a “sell (e+)” rating on shares of MindWalk in a research note on Wednesday, July 15th. Wall Street Zen lowered shares of MindWalk from a “hold” rating to a “sell” rating in a research note on Saturday. JonesTrading initiated coverage on shares of MindWalk in a report on Thursday, April 16th. They set a “buy” rating and a $5.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating on shares of MindWalk in a report on Monday.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its stake in MindWalk by 8.4% in the fourth quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after acquiring an additional 18,600 shares during the last quarter. Bank of Montreal Can raised its holdings in shares of MindWalk by 81.0% in the 4th quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after purchasing an additional 24,500 shares during the period. Virtu Financial LLC bought a new stake in shares of MindWalk in the 4th quarter worth approximately $51,000. XTX Topco Ltd lifted its stake in MindWalk by 118.6% in the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock valued at $149,000 after purchasing an additional 44,331 shares during the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in MindWalk in the fourth quarter valued at approximately $91,000. Hedge funds and other institutional investors own 6.70% of the company’s stock.

MindWalk Stock Up 15.3%

NASDAQ HYFT opened at $1.36 on Friday. The firm has a 50-day simple moving average of $1.56. MindWalk has a 12-month low of $0.99 and a 12-month high of $3.25. The company has a market cap of $63.53 million, a P/E ratio of -6.18 and a beta of 0.83. The company has a quick ratio of 3.64, a current ratio of 2.80 and a debt-to-equity ratio of 0.26.

MindWalk (NASDAQ:HYFT) last released its quarterly earnings data on Wednesday, July 22nd. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The firm had revenue of $3.03 million for the quarter. MindWalk had a negative net margin of 89.65% and a negative return on equity of 92.61%. Equities analysts expect that MindWalk will post -0.17 EPS for the current year.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.